Page 67 - Reconstructive Techniques in Musculoskeletal Tumor Surgery

Pedestal cup endoprosthesis
3
65
Table I. Details of previous reports on endoprosthetic reconstruction of peri-acetabular defects.
Author No. of (year) patients
Follow-up*
Prosthesis used
Indications
Overall complications 58% (including type V)
Infection
Dislocation
Aseptic Local loosening recurrence
Functional outcome 59% (17 to 100)†
Jaiswal et al 2008)16
98
survivors 91 months (3 months to 33.5 years); deceased 33 months (2 months to 11.6 years)
24 months (1 to 61)
Custom made (Stanmore Implants Worldwide Ltd, Stanmore, United Kingdom)
93% primary 7% metastatic
18%
20% recurrent
3% (as a 31% reason for
Witte et al (2009)19
40
MUTARS hemipelvic endoprosthesis (implantcast, Buxtehude, Germany) Modular hemipelvic endoprosthesis
73% primary 28% metastatic
75% (including type V)
30%
3%
revision)
15% 18%
50% (SD 19)†
Guo et al (2007)34
28 27
30 months (10 to 59)
86% primary 14% metastatic 70% primary 7% metastatic 22% failure of previous reconstruction 100% primary
39%
32% 11%
4% 15%
- 25% - 7%
62% (30 to 83)† 69% (52 to 90)†
Fisher et al (2011)4
survivors 39 months (18 to 80) deceased mean 12 months (4 to 27)
‘Ice-cream cone’ coned hemi-pelvis (Stanmore Implants Worldwide Ltd, Stanmore, United Kingdom)
37% (including type V)
Aljassir et al (2005)8 Menendez et al (2009)3
27 25
45 months (3 weeks to 10 years)
29 months (13 to 108)
Saddle prosthesis (Link, Hamburg, Germany) Periacetabular Reconstruction (PAR) prosthesis (Stryker Howmedica, New Jersey, United States) Saddle prosthesis (Link, Hamburg, Germany)
-
37% 24%
22% 12%
- 22% - 20%
51% (SD 22)‡
Aboula a et al (1995)17
17
33 months (15 to 62)
47% primary 53% metastatic or systemic 94% primary 6% metastatic
53%
18%
12%
12% -
59% ‘excellent’ 12% ‘good’ 6% ‘fair’ 24% ‘poor’ 47% (20 to 77)‡ 53% (41to 67)†
Jansen (van de Sande and Dijkstra, 2013)5 Current study
17
survivors median 94 months (2 to 204) deceased median 36 months (2 to 58) survivors 95 months (51 months to 10.5 years) deceased 39 months (28 days to 8.7 years)
Saddle prosthesis (Link, Hamburg, Germany)
82% (not including type V)
53% (as a reason for failure: 18%) 47% (as a reason for failure: 32%)
18% recurrent, 24% single
- 71%
19
Pedestal Cup (Zimmer, Freiburg, Germany)
84% primary 16% metastatic
79% (including type V)
16% recurrent, 11% single
16% 16%
49% (13 to 87)‡
* Mean values, unless stated otherwise, with minimum and maximum or standard deviation (SD) in parentheses † TESS, Toronto extremity salvage score
‡ MSTS, Musculoskeletal Tumor Society Score
32% primary 68% metastatic
56% (including type V)
64% (SD 17)‡ 70% (37 to 90)‡